StageSeries C - III | Alive
Last Raised$10M | 9 mos ago
Vestaron develops peptide-based biopesticides. The company creates biological crop protection products that are effective against insects and related pest species which are harmless to vertebrates such as humans, cats, and dogs. It offers products such as spear-t liquid concentrate, spear-lep, and leprotec. The company was founded in 2005 and is based in Durham, North Carolina.
Missing: Vestaron's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Vestaron's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Research containing Vestaron
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Vestaron in 1 CB Insights research brief, most recently on Jun 9, 2021.
Expert Collections containing Vestaron
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Vestaron is included in 2 Expert Collections, including Advanced Materials.
Startups developing new or improved materials (chemicals, alloys, etc.) that provide physical or functional advantages to basic materials.
Agriculture Technology (Agtech)
Companies that are using technology to make farms more efficient.
Vestaron has filed 21 patents.
The 3 most popular patent topics include:
- Acetylcholinesterase inhibitors
Insecticides, Acetylcholinesterase inhibitors, Molecular biology, Biotechnology, Sustainable agriculture
Insecticides, Acetylcholinesterase inhibitors, Molecular biology, Biotechnology, Sustainable agriculture
Latest Vestaron News
May 10, 2023
Cambridge, Massachusetts, UNITED STATES Susan Altschuller, Ph.D. brings financial management, investor relations, and business planning experience from leading pharmaceutical and biotechnology companies to Cerevel Dr. Altschuller to become CFO effective May 15, 2023 CAMBRIDGE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Susan Altschuller, Ph.D. as chief financial officer (CFO), effective May 15, 2023. “We are excited to welcome Susan to Cerevel, as she brings a breadth of experience leading biopharmaceutical companies by leveraging her strategic understanding, financial expertise, strong scientific background, and engagement with the investment community,” said Tony Coles, M.D. chairperson and outgoing chief executive officer of Cerevel Therapeutics. “Our strong cash position continues to support a robust pipeline of potential therapies and Susan will be a key member of the leadership team as we focus on executing clinical trials and optimizing our cash runway. I also want to express my sincere gratitude to Mark Bodenrader for his important contributions as interim CFO during a time of significant growth at Cerevel.” “I look forward to collaborating with Susan as we track toward seven expected data readouts in 2024,” said Ron Renaud, incoming president and chief executive officer of Cerevel Therapeutics. “Tony and I agree that Susan is a natural fit for Cerevel, with her deep experience in corporate and commercial finance, investor relations, and strategic growth.” “I am impressed by what Cerevel has accomplished to date through creative dealmaking and thoughtful capital formation,” said Dr. Altschuller. “I look forward to joining a fantastic team with exciting days ahead and working together to push boundaries, develop solutions and transform lives of people with some of the most devastating neuroscience diseases.” About Susan Altschuller, Ph.D. Susan Altschuller, Ph.D., MBA has extensive financial management, investor relations, and business planning experience with leading pharmaceutical and biotechnology companies. Most recently, she served as the chief financial officer of ImmunoGen, a biotechnology company developing the next generation of antibody-drug conjugates for cancer patients. Before ImmunoGen, Dr. Altschuller worked at Alexion, where she was head of investor relations and later, head of enterprise finance. Prior to joining Alexion, Dr. Altschuller was head of investor relations at Bioverativ, where she served as the primary interface with Wall Street and led all investor-related activities for the launch of the Biogen hemophilia spin-off. Earlier in her career, Dr. Altschuller held positions at Biogen in various functions of increasing responsibility, including investor relations, corporate finance, and commercial finance. She received a BSE in Biomedical Engineering with Honors from Tulane University, a Ph.D. in Biomedical Engineering from the Illinois Institute of Technology, and an MBA from the MIT Sloan School of Management. Dr. Altschuller serves as audit chair on the Board of Directors of Vestaron Corporation and is a founding Board member of the HNRNP Family Foundation. About Cerevel Therapeutics Cerevel Therapeutics is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling diseases by combining its deep expertise in neurocircuitry with a focus on targeted receptor subtype selectivity and a differentiated approach to pharmacology. Cerevel Therapeutics has a diversified pipeline comprised of five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, Alzheimer’s disease psychosis, epilepsy, panic disorder, and Parkinson’s disease. Headquartered in Cambridge, Mass., Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations, or potential acquisitions. For more information, visit www.cerevel.com . Special Note Regarding Forward-Looking Statements This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements about: the potential attributes and benefits of our product candidates and the format, timing and objectives of our product development activities and clinical trials. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties, including, among others: clinical trial results may not be favorable; uncertainties inherent in the product development process (including with respect to the timing of results and whether such results will be predictive of future results); the impact of COVID-19, the post-COVID environment and other factors on the timing, progress and results of clinical trials; our ability to recruit and enroll suitable patients in our clinical trials; whether and when, if at all, our product candidates will receive approval from the FDA or other regulatory authorities, and for which, if any, indications; competition from other biotechnology companies; uncertainties regarding intellectual property protection; and other risks identified in our SEC filings, including those under the heading “Risk Factors” in our Quarterly Report on Form 10-Q filed with the SEC on May 3, 2023 and our subsequent SEC filings. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Media Contact:
Vestaron Frequently Asked Questions (FAQ)
When was Vestaron founded?
Vestaron was founded in 2005.
Where is Vestaron's headquarters?
Vestaron's headquarters is located at 4025 Stirrup Creek Drive, 400 Suite, Durham.
What is Vestaron's latest funding round?
Vestaron's latest funding round is Series C - III.
How much did Vestaron raise?
Vestaron raised a total of $208.69M.
Who are the investors of Vestaron?
Investors of Vestaron include Grosvenor Food & AgTech, Anterra Capital, Novo Holdings, Northpond Ventures, iSelect Fund and 23 more.
Who are Vestaron's competitors?
Competitors of Vestaron include Solasta Bio and 5 more.
Compare Vestaron to Competitors
Permafuels, Inc. is a Chapel Hill, NC based company that has received a grant(s) from the Department of Energy's SBIR/STTR program. The abstract(s) for these grant award(s) are provided as well since they provide insights into Permafuels, Inc.'s business and areas of expertise. Although biodiesel production using supercritical alcohols is an extremely fast and clean method, it has not been economically competitive with conventional catalytic approaches. This project will optimize the supercritical process to enable cost-effective commercial production of biodiesel fuel.
Neugenesis Corporation is focused on generating better biotherapeutics, cost-effectively. To this end, Neugenesis has developed technology for the discovery, improvement and production of complex proteins; especially heteromeric proteins. The Company's work with the filamentous fungi Neurospora crassa has resulted in significant advances in three important areas of biotechnology: directed evolution, combinatorial biology and recombinant protein expression.
Biosceptre has identified a pan-cancer target, present in many cancer types, and importantly not found in healthy tissue. Early research and initial evidence suggest that drugs directed at the nf-P2X7 target have the potential to redefine cancer therapy. The Company has raised AUD33m and will be raising further capital through both existing and new investors. Biosceptre has a rigorous, international patent portfolio extending to 2032, providing broad protection of the target and specific protection of antibody products. The Company is developing therapeutics and diagnostics to bind nf-P2X7, with the core of product development in topical and systemic cancer drugs. Biosceptreis also developing an immuno-oncology vaccine, through an existing collaboration, and is in discussions with developmental partners to develop diagnostic and imaging technologies to detect and monitor cancer. Biosceptre is supported by a world-class scientific advisory board, the members of which have been central in the development of numerous, highly successful, biotechnology companies and products. The Company has the team, capital, and plan to create substantial value from this unique, patent-protected, technology. The business is headquartered in Cambridge, UK with additional research facilities in Sydney, Australia.
Renewable Oil International is a Florence, AL based company that has received a grant(s) from the Department of Energy's SBIR/STTR program. The abstract(s) for these grant award(s) are provided as well since they provide insights into Renewable Oil International's business and areas of expertise. The project will produce liquid biofuels from wood biomass resources by fast pyrolysis followed by upgrading of the pyrolysis oils. This research will be a key step towards ending global warming, improving national security, and improving rural economies by reducing our dependence on petroleum feedstocks. Declining petroleum resources, combined with increased demand for petroleum by emerging economies, as well as political and environmental concerns about fossil fuels, are causing our society to search for new sources of liquid fuels. This project will develop a method for conversion of biomass into liquid fuels at a small scale called fast pyrolysis—a process whereby biomass is rapidly converted into a liquid biocrude which can be used for fuel oil or upgraded into gasoline and diesel fuels.
Ktedogen is a research-based biotechnology company focussed on the discovery and development of new products from microbial sources. Its technology is based on the isolation from the environment of groups of micro-organisms with the ability to synthesize a variety of natural products. These strains are evaluated in targeted screening programs for the production of classes of antibiotics, of new biological catalysts and for improved processes.
BioVascular Inc. is a privately held biotechnology company that develops drugs and devices for the control of intimal hyperplasia associated with vascular procedures and control of risk factors associated with cardiovascular morbidity and mortality. BioVascular's lead product, saratin, is a polypeptide produced by recombinant means in yeast. This product was licensed from Merck, KGaA in 2005. BioVascular began human clinical trials of saratin for hemodialysis graft access in late 2006 and will begin human trials in the treatment of peripheral artery grafts in early 2007. BioVascular's second product utilizes a mechanism for reduction of a recently defined cardiovascular risk factor. This product will enter human studies in mid 2007.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.